Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-Label, Single-Arm Trial of the Efficacy of Topical Remetinostat on Basal Cell Carcinoma in Patients

Trial Profile

A Phase 2 Open-Label, Single-Arm Trial of the Efficacy of Topical Remetinostat on Basal Cell Carcinoma in Patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remetinostat (Primary)
  • Indications Basal cell cancer; Carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Sep 2019 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
    • 18 Sep 2019 Planned primary completion date changed from 28 Jun 2019 to 28 Jun 2020.
    • 13 May 2019 According to a Medivir AB media release, data from the trial presented at has been presented at the 2019 Society for Investigative Dermatology (SID) annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top